Biblio

Author Title Type [ Year

]

Filters: Author is Chen, Yu-Hong [Clear All Filters]

2020

Tang F-F, Cheng Y-F, Xu L-P, Zhang X-H, Yan C-H, Han W, Chen Y-H, Huang X-J, Wang Y. cGVHD in pediatric haplo-HSCT. Biol Blood Marrow Transplant. 2020.

Zhang J-M, Xu Y, Gale RP, Wu L-X, Zhang J, Feng Y-H, Qin Y-Z, Jiang H, Jiang Q, Jiang B, et al. DPEP1 expression promotes proliferation and survival of leukaemia cells and correlates with relapse in adults with common B cell acute lymphoblastic leukaemia. Br J Haematol. 2020.

Zeng Q-Z, Zhang Y-Y, Wu Y-J, Zhang Z-Y, Zhang J-N, Fu H-X, Wang J-Z, Wang F-R, Yan C-H, Mo X-D, et al. Frequency, risk factors and outcome of active tuberculosis following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020.

Xu Z-L, Cheng Y-F, Zhang Y-Y, Mo X-D, Han T-T, Wang F-R, Yan C-H, Sun Y-Q, Chen Y-H, Tang F-F, et al. The incidence, clinical outcome and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia. Clin Transplant. 2020:e14160.

Tang F-F, Cheng Y-F, Xu L-P, Zhang X-H, Yan C-H, Han W, Chen Y-H, Huang X-J, Wang Y. The incidence, risk factors, and outcomes of acute graft-vs-host disease in pediatric T-cell-replete haploidentical hematopoietic stem cell transplantation. Pediatr Transplant. 2020:e13793.

Tang F-F, Sun Y-Q, Mo X-D, Lv M, Chen Y-H, Wang Y, Xu L-P, Zhang X-H, Huang X-J. The incidence, risk factors, and outcomes of primary prolonged isolated thrombocytopenia after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020.

Chen Q, Zhao X, Fu H-X, Chen Y-H, Zhang Y-Y, Wang J-Z, Wang Y, Wang F-R, Mo X-D, Han W, et al. Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant. 2020.

Bai L, Cheng Y-F, Lu A-D, Suo P, Wang Y, Zuo Y-X, Yan C-H, Wu J, Jia Y-P, Sun Y-Q, et al. Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)/MLL-rearranged B-cell acute lymphoblastic leukemia. Leuk Res. 2020;91:106333.

Liu S-N, Zhang X-H, Xu L-P, Wang Y, Yan C-H, Chen H, Chen Y-H, Han W, Wang F-R, Wang J-Z, et al. Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute GVHD: updated experienced from a large-scale study. Am J Hematol. 2020.

Chang Y-J, Xu L-P, Wang Y, Zhang X-H, Chen H, Chen Y-H, Wang F-R, Han W, Sun Y-Q, Yan C-H, et al. Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody. Bone Marrow Transplant. 2020.

2019

Ma R, Huang X-J, Xu L-P, Liu K-Y, Zhang X-H, Yan C-H, Han W, Wang F-R, Chen Y-H, Chen H, et al. Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies. Biol Blood Marrow Transplant. 2019.

Mo X-D, Zhang X-H, Xu L-P, Wang Y, Yan C-H, Chen H, Chen Y-H, Han W, Wang F-R, Wang J-Z, et al. Corrigendum to 'Interferon α: A potentially effective treatment for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation' [Biology of Blood and Marrow Transplantation 21/11 (2015) 19. Biol Blood Marrow Transplant. 2019.

Mo X-D, Zhang X-H, Xu L-P, Wang Y, Yan C-H, Chen H, Chen Y-H, Han W, Wang F-R, Wang J-Z, et al. Corrigendum to 'Interferon-α is effective for treatment of minimal residual disease in patients with acute leukemia after allogeneic hematopoietic stem cell transplantation: results of a registry study' [Biology of Blood and Marrow Transplantation 23/8 (. Biol Blood Marrow Transplant. 2019.

Zhang Y-Y, Mo X-D, Zhang X-H, Xu L-P, Wang Y, Yan C-H, Chen H, Chen Y-H, Han W, Wang F-R, et al. FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients. Bone Marrow Transplant. 2019.

Wang X-L, Han W, Zhao P, Liu X, Wang J-Z, Wang F-R, Yan C-H, Zhang Y-Y, Mo X-D, Wang Y, et al. Incidence, Risk Factors, Outcomes and Risk Score Model of Acute Pancreatitis after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019.

Wang X-Y, Fan Q-Z, Xu L-P, Wang Y, Zhang X-H, Chen H, Chen Y-H, Wang F-R, Han W, Sun Y-Q, et al. The Quantification of Minimal Residual Disease Pre- and Post-Unmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia. Cytometry B Clin Cytom. 2019.

Xue Y-J, Suo P, Huang X-J, Lu A-D, Wang Y, Zuo Y-X, Yan C-H, Wu J, Kong J, Zhang X-H, et al. Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic leukae. Br J Haematol. 2019.

2018

Xue Y-J, Cheng Y-F, Lu A-D, Wang Y, Zuo Y-X, Yan C-H, Wu J, Sun Y-Q, Suo P, Chen Y-H, et al. Allogeneic hematopoietic stem cell transplantation, especially haploidentical HSCT, may improve long-term survival for high-risk pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era. Biol Blood Marrow Transplant. 2018.

Chang Y-J, Xu L-P, Wang Y, Zhang X-H, Chen H, Chen Y-H, Wang F-R, Han W, Sun Y-Q, Yan C-H, et al. Effects of low-dose glucocorticoid prophylaxis on chronic GVHD and GVHD-free, relapse-free survival after haploidentical transplantation: long-term follow-up of a controlled, randomized open-label trial. Biol Blood Marrow Transplant. 2018.

Huo M-R, Xu Y-J, Zhai S-Z, Lv M, Wang Y, Cao L-Q, Xu L-P, Zhang X-H, Chen H, Chen Y-H, et al. Prevalence and risk factors of antibodies to human leukocyte antigens in haploidentical stem cell transplantation candidates: A multi-center study. Hum Immunol. 2018.

2016

Tang F-F, Huang X-J, Zhang X-H, Chen H, Chen Y-H, Han W, Chen Y, Wang F-R, Wang Y, Wang J-Z, et al. Allogeneic hematopoietic cell transplantation for adult patients with treatment-related acute myeloid leukemia during first remission: Comparable to de novo acute myeloid leukemia. Leuk Res. 2016;47:8-15.

Xu L-P, Xu Z-L, Zhang X-H, Chen H, Chen Y-H, Han W, Chen Y, Wang F-R, Wang J-Z, Wang Y, et al. Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia. Biol Blood Marrow Transplant. 2016.

Zhang X-H, Feng F-E, Han W, Wang F-R, Wang J-Z, Wang Y, Chen Y, Fu H-X, Mo X-D, Zhang Y-Y, et al. High-dose corticosteroid associated with catheter-related thrombosis after allogeneic hematopoietic stem cell transplantation. Thromb Res. 2016;144:6-11.

Mo X-D, Zhang X-H, Xu L-P, Wang Y, Yan C-H, Chen H, Chen Y-H, Han W, Wang F-R, Wang J-Z, et al. Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation in First Complete Remission Can Abrogate the Poor Outcomes of Children with Acute Myeloid Leukemia Resistant to the First Course of Induction Chemotherapy. Biol Blood Marrow Transplant. 2016.

2015

Chen Y, Huang X-J, Wang Y, Liu K-Y, Chen H, Chen Y-H, Zhang X-H, Wang F-R, Han W, Wang J-Z, et al. Febrile reaction associated with the infusion of haploidentical peripheral blood stem cells: incidence, clinical features, and risk factors. Transfusion. 2015.

Pages